ReviewCurrent hypertension reviews2026
Blood Pressure Management in Dialysis: A Comparative Review of Hemodialysis and Peritoneal Dialysis.
Review in Current hypertension reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a major challenge in patients with end-stage kidney disease (ESKD) undergoing dialysis, contributing to increased cardiovascular morbidity and mortality. Both hemodialysis (HD) and peritoneal dialysis (PD) serve as renal replacement therapies, yet their effectiveness in blood pressure (BP) control remains a subject of ongoing debate. Emerging evidence suggests that PD may offer better BP regulation than HD due to continuous ultrafiltration, superior sodium removal, and the preservation of residual kidney function. In contrast, HD is often associated with interdialytic fluid retention, leading to BP fluctuations and a higher risk of cardiovascular complications. However, BP control in PD patients is not without challenges, as ultrafiltration failure, peritoneal membrane dysfunction, and inflammation can contribute to resistant hypertension. Despite these limitations, PD may provide a more stable hemodynamic profile compared to HD, making it a promising option for patients with difficult-to-manage hypertension. Individualized dialysis selection remains crucial, as it balances the benefits of fluid control with the risks of PDrelated complications. Further research, particularly randomized controlled trials, is needed to determine the long-term impact of PD and HD on BP control and cardiovascular outcomes in dialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.